Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
bioXXmed AGHAM:T5O 33 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates HAM:T5O with a GF Score™ of 33/100 and a GF Value™ of €9.07 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 941 Biotechnology companies, bioXXmed AG ranks worse than 84.17% on this metric.
Net margin is calculated as Net Income divided by its Revenue. bioXXmed AG's Net Income for the
six
months ended in Dec. 2025 was €-0.11 Mil. bioXXmed AG's Revenue for the
six
months ended in Dec. 2025 was €0.00 Mil. Therefore, bioXXmed AG's net margin for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for bioXXmed AG's Net Margin % or its related term are showing as below:
HAM:T5O'
s Net Margin % Range Over the Past 10 Years
Min: -142200 Med: -6916.67 Max: -1183.33
Current: -2147.06
HAM:T5O's Net Margin % is ranked worse than 84.17% of 941
companies
in the Biotechnology industry
Industry Median: -88.29
vs HAM:T5O: -2147.06
bioXXmed AG (HAM:T5O) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
bioXXmed AG Net Margin % Related Terms
bioXXmed AG Net Margin % Historical Data
* Premium members only.
The historical data trend for bioXXmed AG's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:T5O vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, bioXXmed AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioXXmed AG Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, bioXXmed AG's Net Margin % distribution charts can be found below:
* The bar in red indicates where bioXXmed AG's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioXXmed AG (HAM:T5O) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on bioXXmed AG and its competitors. According to the industry distribution chart, bioXXmed AG ranks #792 out of 941 companies in the Biotechnology industry, placing it in the top 84.2%.
Is bioXXmed AG's Net Margin % too high?
bioXXmed AG's current Net Margin % is 0.00%. Based on the distribution chart, bioXXmed AG ranks #792 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, bioXXmed AG has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioXXmed AG's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, bioXXmed AG ranks #792 out of 941 companies for Net Margin %. This places bioXXmed AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on bioXXmed AG and its competitors. bioXXmed AG's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioXXmed AG stock overvalued right now?
Based on GuruFocus' analysis, bioXXmed AG (HAM:T5O) is currently considered Possible Value Trap. The stock's GF Value™ is €9.07, compared to a current price of €0.77 — trading 91.5% below its estimated fair value. The current Net Margin % is 0.00%. bioXXmed AG's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For bioXXmed AG (HAM:T5O), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioXXmed AG (HAM:T5O) Overvalued in 2026?
Based on GuruFocus' analysis, bioXXmed AG stock appears to be undervalued.
The current stock price of €0.77 is trading 91.5% below its estimated GF Value™ of €9.07.
GuruFocus considers bioXXmed AG to be Possible Value Trap.
Key valuation signals for HAM:T5O:
Net Margin %: 0.00%
GF Value™: €9.07 vs. price of €0.77 (91.5% below fair value)
No single metric tells the full story. See the HAM:T5O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
33GF Score
Get the complete analysis for HAM:T5O
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:T5O has been successfully added to your 
